Boxer Capital’s Kymera Therapeutics KYMR Stock Holding History

Boxer Capital’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-450,000	Closed	-$21.3M	–	27
2024 Q3	$21.3M	Buy	+450,000	New	+$19.9M	1.05%	26

Other funds holding KYMR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Boxer Capital's KYMR Position: Q4 2024 in Review

Boxer Capital sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 450,000 shares — an estimated $21.3M sold.

Boxer Capital first reported a position in KYMR in Q3 2024 and held it in 1 quarter. The position peaked at $21.3M in Q3 2024. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

Boxer Capital reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 450,000 Kymera Therapeutics shares in Q4 2024, an estimated $21.3M.
Boxer Capital first reported a position in Kymera Therapeutics in Q3 2024 and held it in 1 quarter.
Boxer Capital's Kymera Therapeutics position peaked at $21.3M in Q3 2024.
180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.